The kinetics of specific immune responses in rhesus monkeys inoculated with live recombinant BCG expressing SIV Gag, Pol, Env, and Nef proteins.
Development of an effective preventive or therapeutic vaccine against HIV-1 is an important goal in the fight against AIDS. Effective virus clearance and inhibition of spread to target organs depends principally on the cellular immune response. Therefore, a vaccine against HIV-1 should elicit virus-specific cytotoxic lymphocyte (CTL) responses to eliminate the virus during the cell-associated stages of its life cycle. The vaccine should also be capable of inducing immunity at the mucosal surfaces, the primary route of transmission. Recombinant Bacille Calmette-Guérin (BCG) expressing viral proteins offers an excellent candidate vaccine in view of its safety and ability to persist intracellularly, resulting in the induction of long-lasting immunity and stimulation of the cellular immune response. BCG can be administered orally to induce HIV-specific immunity at the mucosal surfaces. The immunogenicity of four recombinant BCG constructs expressing simian immunodeficiency virus (SIV) Gag, Pol, Env, and Nef proteins was tested in rhesus macaques. A single simultaneous inoculation of all four recombinants elicited SIV-specific IgA and IgG antibody, and cellular immune responses, including CTL and helper T cell proliferation. Our results demonstrate that BCG recombinant vectors can induce concomitant humoral and cellular immune responses to the major proteins of SIV.
Leung
N J
NJ
Department of Medical Microbiology, School of Medicine, University of California, Davis, California, 95616, USA.
Aldovini
A
A
Young
R
R
Jarvis
M A
MA
Smith
J M
JM
Meyer
D
D
Anderson
D E
DE
Carlos
M P
MP
Gardner
M B
MB
Torres
J V
JV
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood*; D001500:BCG Vaccine / Q000235:genetics / Q000276:immunology; D015153:Blotting, Western; D003001:Cloning, Molecular; D003602:Cytotoxicity, Immunologic; D015686:Gene Products, env / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D015683:Gene Products, gag / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D015693:Gene Products, nef / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D015684:Gene Products, pol / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D007070:Immunoglobulin A / Q000097:blood; D007074:Immunoglobulin G / Q000097:blood; D008213:Lymphocyte Activation; D008253:Macaca mulatta; D018449:SAIDS Vaccines / Q000235:genetics / Q000276:immunology*; D016097:Simian Acquired Immunodeficiency Syndrome / Q000517:prevention & control; D015302:Simian Immunodeficiency Virus / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000235:genetics / Q000276:immunology*; D014764:Viral Proteins / Q000235:genetics / Q000276:immunology* / Q000378:metabolism
D000914:Antibodies, Viral; D001500:BCG Vaccine; D015686:Gene Products, env; D015683:Gene Products, gag; D015693:Gene Products, nef; D015684:Gene Products, pol; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D018449:SAIDS Vaccines; D014614:Vaccines, Synthetic; D014764:Viral Proteins